Safety study of dostarlimab for advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study is testing the safety of an immunotherapy drug called dostarlimab (Jemperli) in patients with a type of endometrial cancer that has returned, spread, or not improved after previous chemotherapy. The drug works by helping your immune system fight the cancer, and the study is specifically for patients whose tumors have certain genetic features (dMMR or MSI-H).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have endometrial cancer (cancer of the lining of the uterus) that has spread, come back, or failed to respond after previous treatment with a platinum-based chemotherapy.
- Your tumor has been tested and found to have a high level of microsatellite instability (MSI-H) or to be deficient in mismatch repair (dMMR), which means it may respond to certain immunotherapies.
- If you are a woman who could become pregnant, you agree to use effective birth control during the study and for at least 120 days after your last dose.
- You have not had prior treatment with an immune checkpoint inhibitor (a type of immunotherapy like PD-1 or PD-L1 blockers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called dostarlimab (an immunotherapy that helps your immune system fight cancer) in people with advanced or recurrent endometrial cancer. The goal is to see if the drug is safe and effective for this type of cancer.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
This study tests a new maintenance therapy (mocertatug rezetecan) to help keep endometrial cancer from coming back after initial chemotherapy and immunotherapy. It may help people whose cancer had a good response to first-line treatment.
This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.
This trial tests a new drug called dostarlimab, given with standard chemotherapy, for people with advanced or recurrent endometrial cancer. It aims to see if this combination can help shrink tumors or slow their growth.
This trial tests whether giving the drug dostarlimab before surgery can shrink or control endometrial cancer. It is for people whose tumors have a specific genetic feature (MMR deficiency) that may make the drug more effective.
Hear when a new Neoplasms, Endometrial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.